Bruce J Dezube

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Primary Kaposi sarcoma of the subcutaneous tissue
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    World J Surg Oncol 6:94. 2008
  2. ncbi Pathology of rituximab-induced Kaposi sarcoma flare
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    BMC Clin Pathol 8:7. 2008
  3. ncbi Kaposi sarcoma in unusual locations
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    BMC Cancer 8:190. 2008
  4. ncbi Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science
    Bruce J Dezube
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Cell Physiol 209:659-62. 2006
  5. ncbi Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study
    Bruce J Dezube
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 24:1389-94. 2006
  6. ncbi Imatinib-induced regression of AIDS-related Kaposi's sarcoma
    Henry B Koon
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, CC-913, Boston, MA 02215, USA
    J Clin Oncol 23:982-9. 2005
  7. ncbi HIV-associated anal squamous cell cancer: an otherwise preventable disease
    Panagiotis A Konstantinopoulos
    Division of Hematology/Oncology, and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 24:4516-7. 2006
  8. ncbi Targeted therapy for Kaposi sarcoma
    Ryan J Sullivan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    BioDrugs 23:69-75. 2009
  9. ncbi Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration
    Gabriela A D'Jaen
    Division of Hematology Oncology, Virginia Mason Medical Center, Seattle, WA, USA
    Clin Lung Cancer 11:396-404. 2010
  10. ncbi Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment
    Bruce J Dezube
    AIDS Malignancy Research and Treatment Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    AIDS Read 14:236-8, 243-4, 251-3. 2004

Detail Information

Publications85

  1. ncbi Primary Kaposi sarcoma of the subcutaneous tissue
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    World J Surg Oncol 6:94. 2008
    ..Primary KS of the subcutaneous tissue is an exceptional manifestation of this low-grade vascular neoplasm...
  2. ncbi Pathology of rituximab-induced Kaposi sarcoma flare
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    BMC Clin Pathol 8:7. 2008
    ..CONCLUSION: Rituximab-induced KS flare appears to be related to HHV8 activation. Effective management of iatrogenic KS flare therefore depends upon the control of HHV8 viremia in conjunction with specific chemotherapy for KS...
  3. ncbi Kaposi sarcoma in unusual locations
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    BMC Cancer 8:190. 2008
    ..KS in these atypical sites may prove difficult to diagnose, resulting in patient mismanagement. Theories to explain the rarity and development of KS in these unusual sites are discussed...
  4. ncbi Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science
    Bruce J Dezube
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Cell Physiol 209:659-62. 2006
    ..Recent and future clinical trials of molecularly targeted therapy for the treatment of KS are a prelude to a shift in the paradigm of how KS is managed...
  5. ncbi Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study
    Bruce J Dezube
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 24:1389-94. 2006
    ..The aim of this trial was to extend these initial observations...
  6. ncbi Imatinib-induced regression of AIDS-related Kaposi's sarcoma
    Henry B Koon
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, CC-913, Boston, MA 02215, USA
    J Clin Oncol 23:982-9. 2005
    ..These promising results demonstrate that inhibition of the c-kit and/or PDGF receptors may represent an effective strategy for treating KS...
  7. ncbi HIV-associated anal squamous cell cancer: an otherwise preventable disease
    Panagiotis A Konstantinopoulos
    Division of Hematology/Oncology, and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 24:4516-7. 2006
  8. ncbi Targeted therapy for Kaposi sarcoma
    Ryan J Sullivan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    BioDrugs 23:69-75. 2009
    ..This review focuses on these emerging targets in the treatment of patients with KS and also highlights important clinicopathologic characteristics...
  9. ncbi Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration
    Gabriela A D'Jaen
    Division of Hematology Oncology, Virginia Mason Medical Center, Seattle, WA, USA
    Clin Lung Cancer 11:396-404. 2010
    ..We also sought to compare behavioral characteristics and immunologic features of HIV-LC patients with HIV-positive patients without LC...
  10. ncbi Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment
    Bruce J Dezube
    AIDS Malignancy Research and Treatment Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    AIDS Read 14:236-8, 243-4, 251-3. 2004
    ....
  11. ncbi HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases
    Jorge Castillo
    Division of Hematology Oncology, The Miriam Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island 02906, USA
    Am J Hematol 83:804-9. 2008
    ..PBL is an aggressive B-cell lymphoma that presents in both oral and extra-oral sites of chronically HIV-infected immunosuppressed young men...
  12. ncbi HIV and the breast
    Benjamin E Gewurz
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 15:392-6, 399-402. 2005
    ..In the era of HAART, HIV-infected patients with malignancy--particularly those who have robust CD4+ T-cell counts and well-controlled HIV viral loads--should be treated similarly to their HIV-negative counterparts...
  13. ncbi Images in HIV/AIDS. HIV-associated squamous cell carcinoma of the anus
    Panagiotis A Konstantinopoulos
    Division of Hematology/Oncology, Beth Israel Deconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 16:301-2. 2006
  14. ncbi Multicentric Castleman's disease masquerading as HIV-related lymphoma
    Farshid Dayyani
    Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Am J Med Sci 334:317-9. 2007
    ..His back pain subsided, lymphadenopathy regressed, and he became KSHV/HHV8 negative. Albeit a rare condition, Castleman's disease should always be considered in immunocompromised patients suspected of having lymphoma...
  15. ncbi C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma
    Liron Pantanowitz
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Appl Immunohistochem Mol Morphol 13:162-6. 2005
    ..Furthermore, the expression of c-kit does not correspond with the presence of HHV8 (LNA-1) immunoreactivity in KS lesions...
  16. ncbi HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management
    Elizabeth M Gaughan
    Department of Medicine Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    BMC Urol 9:10. 2009
    ..To date, only a limited number of cases of bladder cancer have been linked with HIV infection. We sought to describe the clinical characteristics of HIV-associated bladder cancer...
  17. ncbi HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease
    Ryan J Sullivan
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Clin Infect Dis 47:1209-15. 2008
    ..The scope of this review is to present contemporary knowledge about the epidemiology, virology, and immunology of Kaposi sarcoma-associated herpesvirus and to highlight several key oncogene products that may be targets for chemotherapy...
  18. ncbi Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma
    Liron Pantanowitz
    Department of Pathology, Beth Israel Deaconess Medical Center, and Department of Pathology, 330 Brookline Avenue, Boston, MA 02215, USA
    J Cutan Pathol 31:26-34. 2004
    ..KS regression has not been well characterized histologically. Therefore, this study was undertaken to characterize the histopathology of pharmacologically induced regressed cutaneous KS...
  19. ncbi The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter
    Hong Li
    Department of Medicine, Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 76:11880-8. 2002
    ..This work demonstrates that the K12 transcript contains variable, complex repeat elements, is spliced and is expressed from a novel KSHV promoter...
  20. ncbi Signal transduction targets in Kaposi's sarcoma
    Ryan Sullivan
    Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Curr Opin Oncol 18:456-62. 2006
    ..These findings and recent clinical trials of targeted therapy for treatment are a prelude to a shift in the paradigm of how AIDS-related Kaposi's sarcoma is managed...
  21. ncbi Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series
    Piro Lito
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Med Sci 337:1-4. 2009
    ..Non-AIDS-defining cancers are an important problem in HIV-infected patients. The occurrence of neuroendocrine (NE) tumors in sites other than the lung and skin has not been well characterized in the setting of concurrent HIV infection...
  22. ncbi Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors
    Anna Berkenblit
    Beth Israel Deaconess Medical Center, and Harvard Cancer Center, Boston, MA, USA
    Clin Cancer Res 13:584-90. 2007
    ..A phase I clinical trial was undertaken to determine the maximum tolerated dose, toxicity profile, and pharmacokinetics of STA-4783 in combination with paclitaxel...
  23. ncbi Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series
    Elizabeth M Gaughan
    Department of Medicine Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Clin Genitourin Cancer 6:86-90. 2008
    ..Our aim was to describe the risk factors, clinical findings, pathology, and response to therapy of RCC in patients infected with HIV...
  24. ncbi HIV-associated intramammary lymphadenopathy
    Panagiotis A Konstantinopoulos
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Breast J 13:192-5. 2007
    ....
  25. ncbi Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study
    Benjamin E Gewurz
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Infect Dis 190:1957-61. 2004
    ..The day 15 median (mean) HIV-1 load decreased by 1.34 (1.45) log(10) copies/mL in the patients receiving 25 mg/kg/day. Capravirine demonstrated potent antiviral activity, even in antiretroviral-experienced patients...
  26. ncbi Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly
    Lisa O Sproat
    Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 37:e170-3. 2003
    ..Clinical resolution occurred only after a splenectomy was performed...
  27. ncbi Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study
    Mary Cianfrocca
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Clin Oncol 20:153-9. 2002
    ..The most common adverse event was dose-related photosensitivity. Antitumor activity was noted. Further evaluation of COL-3 for the treatment of KS is warranted...
  28. ncbi Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  29. ncbi Antimicrobial and non-antimicrobial tetracyclines in human cancer trials
    Christopher Richards
    Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Pharmacol Res 63:151-6. 2011
    ....
  30. ncbi HIV-related gynecomastia
    Liron Pantanowitz
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Breast J 9:131-2. 2003
  31. ncbi Images in HIV/AIDS. Sweet syndrome and syphilis in an HIV-infected person
    Laura E Johnson
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 18:134-5. 2008
  32. ncbi Images in HIV/AIDS. Pericardial primary effusion lymphoma
    Julia M Braza
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 17:250-2. 2007
  33. ncbi Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation
    Chen S Tan
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Infect Dis 199:881-8. 2009
    ....
  34. ncbi Investigational agents for treatment of AIDS-related Kaposi's sarcoma
    Panagiotis A Konstantinopoulos
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Expert Opin Investig Drugs 16:495-504. 2007
    ....
  35. ncbi Human immunodeficiency virus-associated lung carcinoma presenting as cutaneous metastases
    Ayad Hamdan
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Clin Lung Cancer 10:441-4. 2009
    ..With the growing problem of non-AIDS-defining cancers in the current era of HAART, clinicians should be aware that skin lesions in the HIV-infected individual might represent metastatic disease...
  36. ncbi Kaposi's sarcoma
    Liron Pantanowitz
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, USA
    Ear Nose Throat J 83:157. 2004
  37. ncbi Unusual Sites of Malignancies: CASE 3. AIDS-related Kaposi's sarcoma of the gastrointestinal tract
    Weei-Yuarn Huang
    Departments of Pathology and Medicine (Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 23:2098-9. 2005
  38. ncbi Monoclonal antibody hNM01 in HIV-infected patients: a phase I study
    Bruce J Dezube
    Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Virol 31:S45-7. 2004
    ..4 days). During hNMO1 therapy effects were observed on CD4 cell counts and plasma viral loads and further dose finding trials are necessary to better determine the therapeutic activity of hNM01 in HIV-infected individuals...
  39. ncbi A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer
    Manisha H Shah
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, USA
    Clin Cancer Res 12:3993-6. 2006
    ..To determine the safety, toxicity, and immune modulation of this combination of cytokines in vivo, we conducted a first-in-man phase I study...
  40. ncbi A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study
    Bruce J Dezube
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 187:500-3. 2003
    ..24 log(10) and 0.58 log(10), respectively, and, at day 29, were 0.24 log(10 ) and 2.2 log(10), respectively. HRG, administered as a single dose, is reasonably well tolerated and achieves adequate plasma concentrations...
  41. ncbi Advances in the pathobiology and treatment of Kaposi sarcoma
    Liron Pantanowitz
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Curr Opin Oncol 16:443-9. 2004
    ....
  42. ncbi Human Immunodeficiency Virus-associated anaplastic large cell lymphoma
    Kimberly Perez
    Division of Hematology Oncology, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI 02906, USA
    Leuk Lymphoma 51:430-8. 2010
    ..The administration of chemotherapy and early stages at presentation were identified as good prognostic factors, while the use of HAART showed a statistical trend toward improved survival in HIV-associated ALCL...
  43. ncbi Protein electrophoresis and immunoglobulin analysis in HIV-infected patients
    Panagiotis A Konstantinopoulos
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Clin Pathol 128:596-603. 2007
    ..One manifestation of this B-cell response is low-concentration monoclonal banding in 4.4% of the patients studied...
  44. ncbi Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment
    Bruce J Dezube
    Beth Isreal Deaconess Medical Center, Harvard Medical School, USA
    Expert Rev Anticancer Ther 2:193-200. 2002
    ..The next 5 years may also bring a better understanding of the pharmacokinetic interactions among the many agents in the Kaposi's sarcoma and AIDS armamentariums...
  45. ncbi Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients
    Lori A Panther
    Department of Internal Medicine, Division of Infectious Diseases, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 15:79-82, 85-6, 88, 91. 2005
    ..All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts...
  46. ncbi Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma
    Bruce J Dezube
    AIDS Malignancy Research and Treatment Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 14:372-4, 377-9. 2004
    ..In the next few years, it is anticipated that these approaches will be applied more frequently to HIV-infected persons with myeloma...
  47. ncbi Breast enlargement in 13 men who were seropositive for human immunodeficiency virus
    Devon L Evans
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Clin Infect Dis 35:1113-9. 2002
    ..Although most causes of breast enlargement in HIV-infected men are likely to be benign, malignancies other than carcinoma are of concern...
  48. ncbi Characterization of Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 infection of human vascular endothelial cells: early events
    Bruce J Dezube
    Division of Infectious Disease, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Blood 100:888-96. 2002
    ..Although most lytic transcripts accrued until passage, open-reading frame-74 RNAs fluctuated with a fixed periodicity, suggesting that early replication after infection of MVDECs was synchronous...
  49. ncbi Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient
    Daniel B Costa
    Department of Medicine, Division of Hemotology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Natl Med Assoc 98:1183-7. 2006
    ..Our case suggests that poor prognostic factors for adult SCIC patients treated with exchange transfusion may include older age and underlying hepatic disease...
  50. ncbi Growth hormone receptor (GH)-expressing carcinoid tumors after recombinant human GH therapy for human immunodeficiency virus-related lipodystrophy
    Liron Pantanowitz
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 36:370-2. 2003
    ..This case report serves as a cautionary note regarding the use of potentially oncogenic recombinant human growth hormone therapy to treat human immunodeficiency virus-positive persons...
  51. ncbi November 2002: a 72-year-old woman with a pineal gland mass
    Liron Pantanowitz
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass, USA
    Brain Pathol 13:235-6, 239. 2003
    ..The behavior of this circumventricular organ lymphoma was comparable to both peripheral and primary central nervous system lymphomas...
  52. ncbi Pitfalls of diagnosis based on abnormal flow cytometry and [(18)F]fluorodeoxyglucose positron emission tomography
    Parul Bhargava
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Lymphoma Myeloma 8:117-20. 2008
    ..It further underscores the importance of adequate clinical correlation and a low threshold for performing open biopsies in such patients...
  53. ncbi A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial
    Anna Berkenblit
    Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Kirstein 106A, 330 Brookline Avenue, Boston, MA 02215, USA
    Gynecol Oncol 99:50-7. 2005
    ....
  54. ncbi Alpha-chemokine-mediated signal transduction in human Kaposi's sarcoma spindle cells
    Jian-Feng Wang
    Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, MA 02115, USA
    Biochim Biophys Acta 1691:129-39. 2004
    ..IL-8 also enhanced the chemotaxis of KS cells. These results reveal that chemokine-induced signaling pathways may mediate cell growth, transcriptional activation and cell migration in KS...
  55. ncbi The rising challenge of non-AIDS-defining cancers in HIV-infected patients
    John F Deeken
    Division of Hematology Oncology, Georgetown University Medical Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA
    Clin Infect Dis 55:1228-35. 2012
    ..This review presents data on the epidemiology and etiology of NADCs, as well as ongoing research into this evolving aspect of the HIV epidemic...
  56. ncbi Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium
    Yehoshua Maor
    Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Genes Cancer 3:512-20. 2012
    ..This suggests a potential mechanism by which CBD exerts its effects on KSHV-infected endothelium and supports the further examination of CBD as a novel targeted agent for the treatment of Kaposi sarcoma...
  57. ncbi Ovarian carcinoma with thyroid metastases causing clinical hypothyroidism: a case report
    Lara M Skarf
    Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, CC-913, Boston, MA 02215, USA
    Gynecol Oncol 102:394-6. 2006
    ..CONCLUSION: Although uncommon, metastatic disease to the thyroid should be considered when evaluating a patient with advanced ovarian cancer and clinical hypothyroidism...
  58. ncbi High resolution anoscopy findings for men who have sex with men: inaccuracy of anal cytology as a predictor of histologic high-grade anal intraepithelial neoplasia and the impact of HIV serostatus
    Lori A Panther
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 38:1490-2. 2004
    ..The presence of any abnormal anal cytological finding indicates a potential for high-grade dysplasia on histological examination of MSM...
  59. ncbi Unusual sites of Hodgkin's lymphoma: CASE 1. HIV-associated Hodgkin's lymphoma of the stomach
    John Doweiko
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 22:4227-8. 2004
  60. ncbi Management of AIDS-related Kaposi's sarcoma
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, University of Federico II, Naples, Italy
    Lancet Oncol 8:167-76. 2007
    ....
  61. ncbi Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus
    Camilo Raggo
    Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA
    Cancer Res 65:5084-95. 2005
    ..Neither gene has been previously implicated in tumorigenesis. Our data suggest that KSHV-mediated transformation involves exploitation of the hitherto unrealized oncogenic properties of RDC1 and Neuritin...
  62. ncbi Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team
    Ariela Noy
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:990-8. 2005
    ..We report a 24-week, randomized, double-blinded, placebo-controlled phase III trial with the phase II dose, 5 mg intranasally every other day...
  63. ncbi Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA 01199, USA
    J Cutan Pathol 33:793-8. 2006
    ..Their role in KS regression has not been investigated. The aim of this study was to evaluate the expression of multiple MMPs in developing and pharmacologically regressed KS lesions...
  64. ncbi Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series
    Michael C Jacobson
    University of Washington School of Medicine, Seattle, Washington, USA
    Clin Infect Dis 39:1214-22. 2004
    ....
  65. ncbi Reasons for a deficit of breast cancer among HIV-infected patients
    Liron Pantanowitz
    J Clin Oncol 22:1347-8; author reply 1349-50. 2004
  66. ncbi Editorial comment: multiple myeloma and HIV infection--causal or casual coincidence?
    Liron Pantanowitz
    AIDS Read 13:386-7. 2003
  67. ncbi HIV infection masquerading as monoclonal gammopathy of undetermined significance
    Chuanyi M Lu
    N Engl J Med 349:1192-3. 2003
  68. ncbi Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma
    Steven A Miles
    AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, 2001 Third Avenue South, Room 1078, Birmingham, AL 35223, USA
    AIDS 16:421-9. 2002
    ..CONCLUSION: Oral 9-cis-retinoic acid is an active antitumor drug for AIDS-related Kaposi's sarcoma. Treatment is associated with skin and constitutional toxicity and further studies are needed to improve its long-term tolerance...
  69. ncbi AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy
    Matthew C Cheung
    Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Oncologist 10:412-26. 2005
    ..This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era...
  70. ncbi HHV8 is not limited to Kaposi's sarcoma
    Liron Pantanowitz
    Mod Pathol 18:1148; author reply 1149-50. 2005
  71. ncbi Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Gerd Fatkenheuer
    Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
    Nat Med 11:1170-2. 2005
    ..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
  72. ncbi HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients
    Sashi Amara
    Virginia Mason Medical Center, Seattle, WA 98111, USA
    Clin Infect Dis 43:1198-205. 2006
    ..HAART appeared to have a favorable impact on the serum monoclonal protein level in 9 patients. Long-term follow-up is needed to better define the natural history of MGUS and the link to other possible contributing factors...
  73. ncbi HIV-associated multicentric Castleman's disease
    Justin Stebbing
    Department of Medical Oncology, Imperial College School of Science, Technology and Medicine, The Hammersmith Hospitals NHS Trust, London, United Kingdom
    Am J Hematol 83:498-503. 2008
    ..MCD represents a model of disease at the interplay between tumor biology, infection, and immunology...
  74. ncbi Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA 01199, USA
    BJU Int 101:1519-23. 2008
    ....
  75. ncbi AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART
    David M Aboulafia
    Division of Hematology, University of Washington, Seattle, USA
    AIDS Read 14:605-17. 2004
    ..Here we review the epidemiologic and pathobiologic features of AIDS-related lymphoma along with clinical evaluation and treatment options in patients with this disease...
  76. ncbi Kaposi sarcoma of the larynx
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA
    AIDS Read 16:194-5. 2006
  77. ncbi Acute myeloid leukemia in patients infected with HIV-1
    David M Aboulafia
    Division of Hematology/Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    AIDS 16:865-76. 2002
    ....
  78. ncbi Editorial comment: bone lesions in Kaposi sarcoma
    Liron Pantanowitz
    AIDS Read 17:204. 2007
  79. ncbi Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites--the unknown role of underlying HIV infection
    Panagiotis A Konstantinopoulos
    J Natl Med Assoc 98:1860-1. 2006
  80. ncbi Extracavitary primary effusion lymphoma of the anorectum
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Springfield, MA, USA
    Clin Lymphoma Myeloma 6:149-52. 2005
    ..5 years. The purpose of this report is to add another case to the emerging literature regarding the heterogeneous category of extraserous human herpesvirus-8-associated lymphomas...
  81. ncbi Editorial comment: plasmablastic lymphoma--a diagnostic and therapeutic puzzle
    Liron Pantanowitz
    AIDS Read 17:448-9. 2007
  82. ncbi The growing problem of non-AIDS-defining malignancies in HIV
    Liron Pantanowitz
    Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts, USA
    Curr Opin Oncol 18:469-78. 2006
    ..Assertive prevention strategies are needed to adequately deal with non-AIDS-defining cancers in an aging and growing HIV-positive population...
  83. ncbi Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Cancer 112:1147-52. 2008
    ..The current retrospective study investigated the activity and toxicity of PLD in pretreated patients with aggressive, nonvisceral CKS...
  84. ncbi Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study
    Giuseppe Di Lorenzo
    J Invest Dermatol 128:1578-80. 2008
  85. ncbi Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus
    Young-Kwon Hong
    Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Charlestown, Massachusetts 02129, USA
    Nat Genet 36:683-5. 2004
    ....